Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonrotoclax + Zanubrutinib in Previously Untreated Chronic Lymphocytic Leukemia
NCT06637501Phase 2Active, not recruiting
- Sponsor
- BeOne Medicines
- Start
- Nov 2024
- Primary completion
- Nov 2026
- Modality
- Orthosteric Ligands
- Countries
- 6
01
Overview
A Phase 2 trial of sonrotoclax in chronic lymphocytic leukemia (CLL), sponsored by BeOne Medicines. Started Nov 2024; status: active, not recruiting.
02
Drugs
sonrotoclax
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT06637501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06637501.